A provision in new German legislation that requires insurance funds to consider a variety of suppliers will do nothing to address drug shortages because it is not obligatory, local industry association Pro Generika believes.

Lupin’s first-quarter net profit soared nearly 50%, but the strong performance was overshadowed by concerns about regulatory overhang and slower-than-expected scale-up of new products that could jeopardize future revenue growth momentum.

Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.

Firms now have until 23 August to enter the Global Generics & Biosimilars Awards 2019.

Sandoz expects to bring an expedited appeal against a US district court’s finding that two patents protecting Amgen’s Enbrel etanercept brand until 2028 and 2029 are valid. 

International off-patent industry body the IGBA has urged Australia’s government to “hold firm” against intellectual-property proposals made by the European Commission as part of negotiations over an Australia-EU trade deal. The organization believes the EU proposals would negatively impact access to generics and biosimilars in Australia.